CHICAGO (Reuters) - A study of Roche's experimental "armed antibody" found it extended the length of time breast cancer patients lived without their disease getting worse, marking the second successful pivotal trial in this new class of cancer drugs. (Source: Reuters: Health) read more..
Unique Combination of Targeted Antibody Linked to Chemotherapy Shows Positive Results in HER2-Positive Breast Cancer Patients
Results of a large phase III trial shows that a new oncology therapy, trastuzumab emtansine (T-DM1), significantly delays progression of disease in women with HER2-positive advanced breast cancer previously treated with a taxane chemotherapy and trastuzumab (Herceptin). (Source: Cancer Network) read more..
FDA to Let Women Try New Breast Drugs Earlier
Regulators are moving the goal posts in testing new drugs for breast cancer in the hopes of giving more women with aggressive, early-stage cancers the chance to try breakthrough drugs while they have the best shot at a cure.Source: Reuters HealthRelated MedlinePlus Pages: Breast Cancer, Medicines (Source: MedlinePlus Health News) read more..